Company Filing History:
Years Active: 1995-2002
Title: Beatrice Gaugler: Innovator in Cancer Research
Introduction
Beatrice Gaugler is a prominent inventor based in Brussels, Belgium. She has made significant contributions to the field of cancer research, holding a total of 6 patents. Her work focuses on innovative methods for cancer screening and diagnostics.
Latest Patents
Among her latest patents is a method for screening for cancer using binders for MAGE-related peptides and complexes of the peptide and HLA molecules. This invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by the gene MAGE-3. The nonapeptide is presented by the HLA molecule HLA-A1, and the resulting complexes are identified by cytolytic T cells. Such recognition may be utilized in diagnostics or therapeutically. Another notable patent involves isolated nonapeptides presented by HLA molecules, such as HLA-A1. Similar to her previous invention, the resulting complexes are identified by cytolytic T cells, with applications in diagnostics and therapeutic uses.
Career Highlights
Beatrice Gaugler is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues her groundbreaking work in cancer research. Her innovative approaches have the potential to significantly impact cancer diagnostics and treatment.
Collaborations
She has collaborated with notable colleagues in her field, including Benoit Van Den Eynde and Thierry R Boon-Falleur. These collaborations have further enhanced her research and contributions to cancer science.
Conclusion
Beatrice Gaugler's work exemplifies the intersection of innovation and healthcare, particularly in cancer research. Her patents reflect her commitment to advancing diagnostic methods and therapeutic strategies in the fight against cancer.